Satellite Symposium - Bladder Cancer Working Group: Practical Application of Immunotherapeutic Strategies to Optimize Patient Outcomes, Next Steps to Move the Field Forward
Registration and Dinner - 5:30 - 6:00 pm
Scientific Session - 6:00 - 8:00 pm
o Bladder Cancer Working Group: Practical Application of Immunotherapeutic Strategies to Optimize Patient Outcomes, Next Steps to Move the Field Forward is a live symposium to be held adjunct to the annual urology meeting in Chicago. Now, even while clinicians are sorting through data from clinical studies of single-agent immunotherapy for advanced/metastatic urothelial cancer (UC), the field is poised to pivot again as a multitude of ongoing clinical studies are evaluating single-agent and combination immunotherapy strategies across all stages of bladder cancer. Additionally, novel agents are being studied to address the unmet needs of patients who with UC that is refractory to immune checkpoint inhibitor therapy. Use of these agents across multiple lines of therapy for advanced UC and the potential expansion of their use to early-stage disease makes it imperative that urologists, as the primary care provider for patients with early-stage disease and the gatekeep for referral to other specialists, understand both new data and best practices related to the use of immunotherapy, including proactively monitoring, mitigating, and managing immune-related adverse events. This interactive symposium will bring together a multidisciplinary faculty of renowned experts in urology, medical oncology, and immunotherapy to review practice-changing data and discuss their impact on patient care. Brief didactic presentations will be followed by “real-world” clinical case presentations and discussions that facilitate interpretation and application of the evidence. The faculty will also share their forward-looking perspectives on the bladder cancer treatment horizon based on recently reported and anticipated clinical trial data. Come hear the experts’ talk about your most pressing clinical questions and challenges, including topics such as optimal treatment selection, duration of treatment, sequencing, as well as identification and management of pseudoprogression and unique toxicities.
Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant from Merck & Co., Inc.